Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P17405

UPID:
ASM_HUMAN

ALTERNATIVE NAMES:
Acid sphingomyelinase

ALTERNATIVE UPACC:
P17405; A8K8M3; E9PKS3; P17406; Q13811; Q16837; Q16841

BACKGROUND:
Acid sphingomyelinase, with its alternative name Sphingomyelin phosphodiesterase, is integral in sphingomyelin metabolism, converting it to ceramide. It is involved in various cellular processes, including cholesterol transport, apoptosis modulation, and membrane repair. The enzyme's activity is crucial for maintaining cellular homeostasis and responding to stress and infections.

THERAPEUTIC SIGNIFICANCE:
Mutations affecting this enzyme cause Niemann-Pick disease types A and B, with symptoms ranging from neurodegeneration to hepatosplenomegaly. Exploring the therapeutic potential of modulating this enzyme's activity offers hope for treating these debilitating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.